Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 8 of 30
Language Network Prehab Via fMRI Neurofeedback
NCT07488780
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
NCT07176351
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NCT07398950
The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls
NCT05014074
A Virtual Reality Game to Prevent E-cigarette and Cannabis Vaping
NCT07413432
Pilot Evaluation of Digital Peer-Support Intervention for College Students
NCT07460635
Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks
NCT05641766
Overdiagnosis and Breast Cancer Screening Decisions
NCT07071415
Feasibility Study on PoRi Device
NCT06842901
Comparing Mirror Therapy Rehabilitation Device to Conventional Mirror Therapy
NCT06842888
Adaptive Decision Support for Addiction Treatment (ADAPT) Factorial Trial
NCT06793696
STOP (Shared Decision Making to Treat Or Prevent) HIV in Justice Populations
NCT06439329
Electronic Health Record Strategies to Promote Diverse Participation in Research AIM 2
NCT06467487
Effect of Different E-cigarette Cooling Flavors on Adults' Sensory Experience TCORS 3.0
NCT05932693
Adolescent Depression: Video Ads on Instagram
NCT05755165
Role Of Non-Specific Effects in The Treatment of Depression With Esketamine
NCT05910775
Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment
NCT06139016
ABC-CT Pre-School Feasibility Study
NCT06413316
Telehealth Treatment for Opioid Use Disorders
NCT05832879
Sex Differences in E-cig Perception: Study 1
NCT05432830
Rehabilitation Device for Hand Mirror Therapy
NCT06296628
Quit Smoking Text Message Study
NCT06111755
Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
NCT06261905
Learning Alerts for Acute Kidney Injury
NCT02786277
Binge Eating Self-help for Teens ONLINE Pilot and Feasibility Study
NCT06107387
Social Support Intervention for Addiction Recovery
NCT06022107
ECMO Hemostatic Transfusions in Children
NCT05796557
Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy
NCT06002152
Audiovisual Interactive Games to Alleviate Pediatric Perioperative Anxiety
NCT06111742
Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes
NCT06098729
The SMART-LV Pilot Study
NCT05630170
Tka Assay for CDK4/6i
NCT06572800
Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus
NCT05934903
Metabolism in the Human Brain Following Consumption of a Keto-ester in Alcohol Use Disorder (AUD) With Proton Magnetic Resonance Spectroscopic Imaging (MRSI)
NCT05937893
Feasibility and Impact of the FOOD4MOMS Produce Prescription Program Among Pregnant Latina Women
NCT05907616
Digitalization of Measuring Physical Performance
NCT06564350
The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery
NCT05676294
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
NCT05776875
Janus Kinase Inhibition in Sarcoidosis
NCT05696795
Investigating Real-world Stress-related Mechanisms in Heavy Cannabis Users
NCT05833230
Artificial Intelligent Clinical Decision Support System Simulation Center Study for Technology Acceptance
NCT05816473
Digital Mindfulness-Based Treatment for Substance Use Disorder Recovery
NCT05852015
Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
NCT05736224
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
NCT05447286
The LEARN Study for CVD Prevention
NCT05242952
Investigating the Impact of a Shared Decision-Making Tool
NCT05411939
WHOOP Abnormal Rhythm Notification
NCT05809362
Project INSPIRE: INtervention Support Groups: Peers Inspiring Resilience and Empowerment
NCT05826041
Artificial Intelligence + Care Coach Intervention
NCT05352399
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 1
NCT05560932
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.